Logo for Rezolute Inc

Rezolute Investor Relations Material

Latest events

Logo for Rezolute Inc

AGM 2024

Rezolute
Logo for Rezolute

AGM 2024

5 Dec, 2024
Logo for Rezolute

Q1 2025

6 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Rezolute Inc

Access all reports
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases, particularly those related to chronic glucose imbalances. The company's lead product, RZ358, is a human monoclonal antibody currently in clinical trials aimed at treating congenital hyperinsulinism, a rare pediatric disorder. Additionally, Rezolute is working on RZ402, an oral plasma kallikrein inhibitor, intended for the treatment of diabetic macular edema. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.